Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PULM
stocks logo

PULM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q3
FY2023Q4
1.86M
-0.53%
-1.050
-27.59%
1.77M
+3.69%
-1.040
-8.77%
Estimates Revision
Stock Price
Go Down
down Image
-12.32%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Pulmatrix Inc (PULM.O) is -0.86, compared to its 5-year average forward P/E of -1.19. For a more detailed relative valuation and DCF analysis to assess Pulmatrix Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.19
Current PE
-0.86
Overvalued PE
-0.28
Undervalued PE
-2.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.06
Current PS
0.00
Overvalued PS
11.41
Undervalued PS
-1.28
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PULM News & Events

Events Timeline

(ET)
2025-10-16
08:16:04
Pulmatrix announces Q3 earnings per share of 24 cents, compared to a loss of 71 cents in the previous year.
select
2025-10-16
08:07:36
Pulmatrix Considering Sale of Patent Portfolio for iSPERSE Technology
select
2025-08-06 (ET)
2025-08-06
08:12:23
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
10-16PRnewswire
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

  • Proposed Merger with Cullgen: Pulmatrix is advancing a merger with Cullgen, a biopharmaceutical company focused on targeted protein degradation therapies, while planning to divest its proprietary iSPERSE™ technology and related clinical programs, including a Phase 2-ready migraine treatment.

  • Financial Performance: In Q3 2025, Pulmatrix reported a decrease in revenues and operating expenses, with total cash and cash equivalents at $4.8 million, which is expected to sustain operations into Q4 2026.

[object Object]
Preview
9.5
08-07NASDAQ.COM
Pulmatrix (PULM) Q2 Revenue Falls 100%

  • Financial Performance: Pulmatrix reported zero revenue in Q2 2025, with a net loss per share of $(0.42), significantly reduced from $(1.59) in the same quarter last year, primarily due to drastic cuts in R&D spending as the company winds down its clinical operations.

  • Strategic Focus: The company is concentrating on completing its merger with Cullgen and divesting its iSPERSE™ intellectual property and clinical programs, while offering no financial guidance for future quarters amid ongoing operational downsizing.

[object Object]
Preview
9.5
08-06PRnewswire
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

  • Proposed Merger Details: Pulmatrix, Inc. is set to merge with Cullgen, a clinical-stage biopharmaceutical company, anticipated to close in 2025, pending regulatory approvals and other conditions. The merger aims to create a Nasdaq-listed entity focused on targeted protein degradation therapies.

  • Divestment of iSPERSE™ Technology: As part of the merger, Pulmatrix plans to divest its proprietary iSPERSE™ dry powder delivery technology and related clinical programs, which are designed for inhalation-based drug delivery to treat various diseases, including migraines and respiratory conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pulmatrix Inc (PULM) stock price today?

The current price of PULM is 4.27 USD — it has decreased -3.61 % in the last trading day.

arrow icon

What is Pulmatrix Inc (PULM)'s business?

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

arrow icon

What is the price predicton of PULM Stock?

Wall Street analysts forecast PULM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PULM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pulmatrix Inc (PULM)'s revenue for the last quarter?

Pulmatrix Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Pulmatrix Inc (PULM)'s earnings per share (EPS) for the last quarter?

Pulmatrix Inc. EPS for the last quarter amounts to -0.24 USD, decreased -66.20 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pulmatrix Inc (PULM)'s fundamentals?

The market is revising No Change the revenue expectations for PULM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -12.32%.
arrow icon

How many employees does Pulmatrix Inc (PULM). have?

Pulmatrix Inc (PULM) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Pulmatrix Inc (PULM) market cap?

Today PULM has the market capitalization of 15.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free